These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39487373)

  • 1. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
    Hamilton EP; Falchook GS; Wang JS; Fu S; Oza AM; Imedio ER; Kumar S; Ottesen L; Mugundu GM; de Bruin EC; O'Connor MJ; Jones SF; Spigel DR; Li BT
    Target Oncol; 2024 Nov; 19(6):879-892. PubMed ID: 39487373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E; Rathmell WK; Shapiro GI; Takebe N; Rodon J; Mahalingam D; Trikalinos NA; Kalebasty AR; Parikh M; Boerner SA; Balido C; Krings G; Burns TF; Bergsland EK; Munster PN; Ashworth A; LoRusso P; Aggarwal RR
    Cancer Res Commun; 2024 Jul; 4(7):1793-1801. PubMed ID: 38920407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
    Dawson R; Diacon AH; De Jager V; Narunsky K; Moodley VM; Stinson KW; Liu Y; Zheng B; Hafkin J
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39612928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma.
    Wei M; Liu R; Xu Y; Chen X; Liu C; Bai X; Zhang X; Gao S; Li J; Sheng Z; Lian J; Wang W; Zhang J; Shi S; Xu J; Yu X
    BMC Med; 2024 Sep; 22(1):365. PubMed ID: 39232761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial.
    Sureda A; Pinto A; Ghesquières H; Morschhauser F; Tournilhac O; Mutsaers P; Zijlstra JM; De Filippi R; Hilgier K; Manamley N; Janik T; Zinzani PL
    Hematol Oncol; 2025 Jan; 43(1):e70000. PubMed ID: 39617826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
    Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
    Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD; D'Cruz D; Kalunian K; Merrill JT; Navarra SV; Cahuzac C; Cornelisse P; Murphy MJ; Strasser DS; Trokan L; Berkani O
    Lancet Rheumatol; 2024 Nov; ():. PubMed ID: 39586304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial of a Novel Formulation of Ketorolac Tromethamine for Continuous Infusion (NTM-001) in Healthy Volunteers.
    Pergolizzi JV; Batra A; Schmidt WK
    Adv Ther; 2024 Feb; 41(2):659-671. PubMed ID: 38070041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With
    Sweis RF; Gajate P; Morales-Barrera R; Lee JL; Necchi A; de Braud F; Penel N; Grünwald V; Maruzzo M; Meran J; Ishida TC; Bao W; Zhou Y; Ellinghaus P; Rosenberg JE
    JAMA Oncol; 2024 Nov; 10(11):1565-1570. PubMed ID: 39298147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
    Lim AWY; Schneider L; Loy C
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD001747. PubMed ID: 39498781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors.
    Spigel DR; Wang JS; Pronk L; Muskens B; Teufel M; Bashir B; Burris H
    ESMO Open; 2024 Nov; 9(11):103730. PubMed ID: 39617535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.